Eve Health Group Limited has released a press release.
Appendix 4E
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4e-211
6ix hasn’t read this filing yet.
EVE Health Group Limited on 6ix
Earlier from EVE Health
- Aust Regulatory Path Cleared for ED & Dysmenorrhea Products
- EVE Submits First Commercial Purchase Order for Dyspro
- Prescribing Agreement for ED and Dysmenorrhea Products
- EVE Completes Nextract Acquisition
- Results of Meeting
Later from EVE Health
- Appointment of Dr Fiona Cousins to Scientific Advisory Board
- Eve Commences Distribution of Dyspro
- Dyspro Prescribed to First Patients
- EVE Raises $1.1m to Accelerate Launches of Dyspro and Libbo
- Medical Science Liaison Appointed
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health